BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $856 | -18.4% | 12,570 | -2.2% | 0.01% | -16.7% |
| Q2 2023 | $1,049 | -23.9% | 12,849 | -30.8% | 0.01% | -40.0% |
| Q1 2023 | $1,378 | -13.6% | 18,580 | -3.4% | 0.01% | 0.0% |
| Q4 2022 | $1,594 | -99.9% | 19,237 | +309.4% | 0.01% | 0.0% |
| Q3 2022 | $1,334,000 | -9.1% | 4,699 | +11.0% | 0.01% | -9.1% |
| Q2 2022 | $1,468,000 | +7.8% | 4,235 | +34.6% | 0.01% | +10.0% |
| Q1 2022 | $1,362,000 | -21.9% | 3,146 | -6.6% | 0.01% | -23.1% |
| Q4 2021 | $1,743,000 | +15.6% | 3,369 | +8.3% | 0.01% | +8.3% |
| Q3 2021 | $1,508,000 | +39.0% | 3,112 | +29.1% | 0.01% | +33.3% |
| Q2 2021 | $1,085,000 | +50.3% | 2,410 | +27.6% | 0.01% | +28.6% |
| Q1 2021 | $722,000 | +57.3% | 1,889 | +30.7% | 0.01% | +40.0% |
| Q4 2020 | $459,000 | +67.5% | 1,445 | +30.9% | 0.01% | +66.7% |
| Q3 2020 | $274,000 | +37.0% | 1,104 | +45.6% | 0.00% | 0.0% |
| Q2 2020 | $200,000 | – | 758 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |